Hepion Pharmaceuticals, Inc. (CTRVP) SEC Filings — 2024

Filings

• Hepion Pharmaceuticals Files S-1 for Securities Offering — S-1 · Dec 26, 2024
• Hepion Pharmaceuticals Terminates Material Agreement — 8-K · Dec 11, 2024
• Hepion Pharma Files Proxy Materials for P2B001 Presentation — DEFA14A · Dec 5, 2024
• Hepion Pharma Urges Shareholder Support in DEFA14A Filing — DEFA14A · Dec 2, 2024
• Hepion Pharmaceuticals Fails Nasdaq Listing Standards — 8-K · Nov 21, 2024
• Hepion Pharmaceuticals, Inc. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Hepion Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 14, 2024
• Hepion Pharmaceuticals Faces Nasdaq Delisting Warning — 8-K · Sep 5, 2024
• Hepion Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 13, 2024
• Hepion Pharmaceuticals Board Changes and Officer Compensation — 8-K · Aug 7, 2024
• Hepion Pharmaceuticals Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Jul 22, 2024
• Hepion Pharmaceuticals Files S-1 for Securities Offering — S-1 · Jul 11, 2024
• Hepion Pharmaceuticals Files 2023 Annual Report Amendment — 10-K/A · Jun 25, 2024
• Hepion Pharmaceuticals Files Q1 2024 10-Q — 10-Q · May 21, 2024
• Hepion Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Apr 16, 2024
• Hepion Pharmaceuticals Announces Executive and Board Changes — 8-K · Mar 6, 2024
• Hepion Pharmaceuticals Announces Executive Leadership Changes — 8-K · Feb 20, 2024
• Hepion Pharma Sells Equity in Unregistered Offering — 8-K · Feb 16, 2024
• Hepion Pharmaceuticals, Inc. SC 13G Filing — SC 13G · Feb 14, 2024
• Hepion Pharma Appoints Dr. Todd Hobbs to Board of Directors — 8-K · Feb 7, 2024
• Hepion Pharma Changes Accountants, No Reason Disclosed — 8-K · Jan 3, 2024